title: Acquired haemophilia A after stem cell transplant for sickle cell disease: treatment with recombinant porcine factor VIII (OBI-1) and tolerance induction with rituximab/prednisone.
authors.affiliation: Department of Laboratory Medicine, National Institutes of Health Clinical Center, Bethesda, MD, USA.
authors.forename: J N
authors.initials: JN
authors.lastname: Lozier
authors.forename: K
authors.initials: K
authors.lastname: Nghiem
authors.forename: M
authors.initials: M
authors.lastname: Lee
authors.forename: B
authors.initials: B
authors.lastname: Hodsdon
authors.forename: G
authors.initials: G
authors.lastname: Joe
authors.forename: R
authors.initials: R
authors.lastname: P Weitzel
authors.forename: J F
authors.initials: JF
authors.lastname: Tisdale
authors.forename: M
authors.initials: M
authors.lastname: Hsieh
mesh_terms: D000328:Adult; D000755:Anemia, Sickle Cell / Q000150:complications* / Q000628:therapy; D000818:Animals; D000906:Antibodies / Q000097:blood / Q000276:immunology; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D005169:Factor VIII / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006467:Hemophilia A / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood / Q000276:immunology; D008297:Male; D011241:Prednisone / Q000627:therapeutic use; D000069283:Rituximab
chemical_list: D000906:Antibodies; D058846:Antibodies, Monoclonal, Murine-Derived; D007074:Immunoglobulin G; D000069283:Rituximab; D005169:Factor VIII; D011241:Prednisone